Objectives Patients with systemic lupus erythematosus (SLE) are at high risk of cardiovascular disease (CVD), fragility fractures, and malignancies. However, data regarding these comorbidities among Chinese SLE patients are limited. We aimed to determine the prevalence of and risk factors for these three major comorbidities in a large cohort of Chinese SLE patients. Methods In this cross-sectional study, demographic, clinical, and common comorbidity profiles were obtained from the medical records of SLE patients enrolled in the Chinese SLE Treatment and Research group (CSTAR) registry. Univariate and multivariate logistic regression analyses were performed to identify possible risk factors related to these comorbidities. Results A total of 38,105 SLE patients were included (92.2% women). The median age at registration was 34.0 years (interquartile range, 27.0–46.0 years). The prevalence rates of the three important comorbidities at baseline were as follows: CVD, 1.9% (95% confidence interval [CI]: 1.8–2.0%); fragility fractures, 0.7% (95% CI: 0.6–0.8%); and malignancies, 0.7% (95% CI: 0.6–0.8%). In the multivariable-adjusted model, lupus anticoagulant, anticardiolipin antibody, anti-β2GP1 antibody, neuropsychiatric involvement, and hematological involvement were positively associated with CVD in SLE patients. Mucocutaneous manifestations, hyperimmunoglobulinemia, hypocomplementemia, anti-dsDNA, anti-Sm, and anti-nRNP/U1RNP antibody, and hydroxychloroquine therapy were negatively associated with CVD. The multivariate analysis revealed that age older than 50 years and hypocomplementemia were associated with fragility fractures and malignancies. Conclusion CVD, fragility fractures, and malignancies commonly occur in SLE patients. Patients with traditional and SLE-related factors should be more carefully monitored for these important comorbidities. <Table Float="No" ID="Taba"> <tgroup cols="2"> <colspec align="left" colname="c1" colnum="1" /> <colspec align="left" colname="c2" colnum="2" /> <tbody> <row> <entry align="left" nameend="c2" namest="c1"> Key Points • SLE patients have an increased risk of cardiovascular disease, fragility fractures, and malignancy. However, data regarding these comorbidities among Chinese SLE patients are limited. • Several associated risk factors for these three comorbidities of SLE were identified.Characteristics, symptom severity, and QOL differ in different age groups. • Lupus patients with traditional and SLE-related factors should be more carefully monitored for the presence of these comorbidities. </entry> </row> </tbody> </tgroup> </Table>

Prevalence of and risk factors for important comorbidities of systemic lupus erythematosus using data from a multicenter Chinese cohort registry: A cross-sectional study

期刊论文
发表日期：

2025年5月16日

查看全文

Minhui Wang,
Jiaxin Zhou,
Feng Zhan,
Hui Luo,
Xinwang Duan,
Cheng Zhao,
Zhenbiao Wu,
Hongbin Li,
Min Yang,
Qin Li,
Jian Xu,
Can Huang,
Jiuliang Zhao,
Qian Wang,
Xiaomei Leng,
Xinping Tian,
Yan Zhao,
Xiaofeng Zeng,
Heng Cao,
Mengtao Li

摘要

Objectives

Patients with systemic lupus erythematosus (SLE) are at high risk of cardiovascular disease (CVD), fragility fractures, and malignancies. However, data regarding these comorbidities among Chinese SLE patients are limited. We aimed to determine the prevalence of and risk factors for these three major comorbidities in a large cohort of Chinese SLE patients.

Methods

In this cross-sectional study, demographic, clinical, and common comorbidity profiles were obtained from the medical records of SLE patients enrolled in the Chinese SLE Treatment and Research group (CSTAR) registry. Univariate and multivariate logistic regression analyses were performed to identify possible risk factors related to these comorbidities.

Results

A total of 38,105 SLE patients were included (92.2% women). The median age at registration was 34.0 years (interquartile range, 27.0–46.0 years). The prevalence rates of the three important comorbidities at baseline were as follows: CVD, 1.9% (95% confidence interval [CI]: 1.8–2.0%); fragility fractures, 0.7% (95% CI: 0.6–0.8%); and malignancies, 0.7% (95% CI: 0.6–0.8%). In the multivariable-adjusted model, lupus anticoagulant, anticardiolipin antibody, anti-β2GP1 antibody, neuropsychiatric involvement, and hematological involvement were positively associated with CVD in SLE patients. Mucocutaneous manifestations, hyperimmunoglobulinemia, hypocomplementemia, anti-dsDNA, anti-Sm, and anti-nRNP/U1RNP antibody, and hydroxychloroquine therapy were negatively associated with CVD. The multivariate analysis revealed that age older than 50 years and hypocomplementemia were associated with fragility fractures and malignancies.

Conclusion

CVD, fragility fractures, and malignancies commonly occur in SLE patients. Patients with traditional and SLE-related factors should be more carefully monitored for these important comorbidities.

Key Points

• SLE patients have an increased risk of cardiovascular disease, fragility fractures, and malignancy. However, data regarding these comorbidities among Chinese SLE patients are limited.

• Several associated risk factors for these three comorbidities of SLE were identified.Characteristics, symptom severity, and QOL differ in different age groups.

• Lupus patients with traditional and SLE-related factors should be more carefully monitored for the presence of these comorbidities.